{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:01:52Z","timestamp":1792083712635,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University Medical Center Ljubljana","award":["20220095"],"award-info":[{"award-number":["20220095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04750-2","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:55:39Z","timestamp":1768323339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Three decades of experience with therapeutic apheresis at a tertiary academic center: review of indications, clinical practice, special age groups and complications"],"prefix":"10.1186","volume":"27","author":[{"given":"Alexander","family":"Jerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Andonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana \u017dupunski","family":"\u010cede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fornazari\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Guben\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja Marn","family":"Pernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Medved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ponikvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmen","family":"Romozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Vajdi\u010d","family":"Trampu\u017e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Zrim\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Per\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"4750_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/asheducation-2012.1.7","volume":"2012","author":"JL Winters","year":"2012","unstructured":"Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American society for apheresis guidelines. Hematol Am Soc Hematol Educ Program. 2012;2012:7\u201312. https:\/\/doi.org\/10.1182\/asheducation-2012.1.7.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"4750_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jca.21311","volume":"29","author":"J Strauchmann","year":"2014","unstructured":"Strauchmann J, et al. Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. J Clin Apheresis. 2014;29(5):235\u201342. https:\/\/doi.org\/10.1002\/jca.21311.","journal-title":"J Clin Apheresis"},{"issue":"1","key":"4750_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jca.21261","volume":"28","author":"RB Ibrahim","year":"2013","unstructured":"Ibrahim RB, Balogun RA. Medications and therapeutic apheresis procedures: are we doing our best? J Clin Apheresis. 2013;28(1):73\u20137. https:\/\/doi.org\/10.1002\/jca.21261.","journal-title":"J Clin Apheresis"},{"key":"4750_CR4","doi-asserted-by":"publisher","unstructured":"Krzych \u0141J, Czok M, Putowski Z. Is antimicrobial treatment effective during therapeutic plasma exchange? Investigating the role of possible interactions. Pharmaceutics. 2020 Apr;12(5):395. https:\/\/doi.org\/10.3390\/pharmaceutics12050395.","DOI":"10.3390\/pharmaceutics12050395"},{"key":"4750_CR5","doi-asserted-by":"publisher","unstructured":"Mahmoud SH, Buhler J, Chu E, Chen SA, Human T. Drug dosing in patients undergoing therapeutic plasma exchange. Neurocrit Care. 2021 Feb;34(1):301\u201311. https:\/\/doi.org\/10.1007\/s12028-020-00989-1.","DOI":"10.1007\/s12028-020-00989-1"},{"key":"4750_CR6","doi-asserted-by":"publisher","unstructured":"Connelly-Smith L, et al. Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence\u2010based approach from the writing committee of the American society for apheresis: the ninth special issue. J Clinical Apheresis. 2023 Apr;38(2):77\u2013278. https:\/\/doi.org\/10.1002\/jca.22043.","DOI":"10.1002\/jca.22043"},{"key":"4750_CR7","doi-asserted-by":"publisher","unstructured":"Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis. 2008 Dec;52(6):1180\u201396. https:\/\/doi.org\/10.1053\/j.ajkd.2008.02.360.","DOI":"10.1053\/j.ajkd.2008.02.360"},{"key":"4750_CR8","doi-asserted-by":"publisher","unstructured":"Cervantes CE, Bloch EM, Sperati CJ. Therapeutic plasma exchange: core curriculum 2023. Am J Kidney Dis. 2023 Apr;81(4):475\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.017.","DOI":"10.1053\/j.ajkd.2022.10.017"},{"key":"4750_CR9","doi-asserted-by":"publisher","unstructured":"Williams ME, Balogun RA. Principles of separation: indications and therapeutic targets for plasma exchange. CJASN. 2014 Jan;9(1):181\u201390. https:\/\/doi.org\/10.2215\/CJN.04680513.","DOI":"10.2215\/CJN.04680513"},{"key":"4750_CR10","doi-asserted-by":"publisher","unstructured":"Levin PD, Levin V, Weissman C, Sprung CL, Rund D. Therapeutic plasma exchange as treatment for propofol infusion syndrome. J Clin Apher. 2015 Oct;30(5):311\u201313. https:\/\/doi.org\/10.1002\/jca.21376.","DOI":"10.1002\/jca.21376"},{"key":"4750_CR11","doi-asserted-by":"publisher","unstructured":"Poisson JL, Low A, Park YA. The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange. J Clin Apher. 2013 Aug;28(4):317\u201320. https:\/\/doi.org\/10.1002\/jca.21253.","DOI":"10.1002\/jca.21253"},{"key":"4750_CR12","doi-asserted-by":"publisher","unstructured":"Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec;39(6):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","DOI":"10.1200\/JCO.21.01440"},{"issue":"4","key":"4750_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jca.21899","volume":"36","author":"J Gubensek","year":"2021","unstructured":"Gubensek J, Ponikvar R, Premru Srsen T, Fabjan Vodusek V, Moertl MG, Lucovnik M. Therapeutic plasma exchange and dextran-sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restriction. J Clin Apheresis. 2021;36(4):595\u2013605. https:\/\/doi.org\/10.1002\/jca.21899.","journal-title":"J Clin Apheresis"},{"key":"4750_CR14","doi-asserted-by":"publisher","unstructured":"Guben\u0161ek J, Ponikvar R, Premru T, Sr\u0161en V, Fabjan Vodu\u0161ek MG, Moertl, Lu\u010dovnik M. Treatment of preeclampsia at extremely preterm gestation with therapeutic plasma exchange. Clin Nephrol. 2021 Suppl;96(1):101\u20136. https:\/\/doi.org\/10.5414\/CNP96S18.","DOI":"10.5414\/CNP96S18"},{"key":"4750_CR15","doi-asserted-by":"publisher","unstructured":"Thadhani R, et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol. 2016 Mar;27(3):903\u201313. https:\/\/doi.org\/10.1681\/ASN.2015020157.","DOI":"10.1681\/ASN.2015020157"},{"key":"4750_CR16","doi-asserted-by":"publisher","unstructured":"Winkler K, et al. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: the Freiburg preeclampsia H.E.L.P.-Apheresis study. Pregnancy Hypertens. 2018 Apr;12:136\u201343. https:\/\/doi.org\/10.1016\/j.preghy.2018.04.007.","DOI":"10.1016\/j.preghy.2018.04.007"},{"issue":"4","key":"4750_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000513123","volume":"48","author":"B Stegmayr","year":"2021","unstructured":"Stegmayr B, et al. Using the world apheresis association registry helps to improve the treatment quality of therapeutic apheresis. TMH. 2021;48(4):234\u20139. https:\/\/doi.org\/10.1159\/000513123.","journal-title":"TMH"},{"key":"4750_CR18","doi-asserted-by":"publisher","unstructured":"Basic-Jukic N, Brunetta B, Kes P. Plasma exchange in elderly patients. Therapeutic Apheresis Dialysis. 2010 Apr;14(2):161\u20135. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00793.x.","DOI":"10.1111\/j.1744-9987.2009.00793.x"},{"key":"4750_CR19","doi-asserted-by":"publisher","unstructured":"Zrimsek M, Gubensek J, Marn Pernat A. A pilot study on the replacement of fibrinogen with fibrinogen concentrates during therapeutic plasma exchange with mild to moderate bleeding risk\u2014a comparison with fresh frozen plasma and albumin replacement. J Clin Med. 2024 Jan;13(24). https:\/\/doi.org\/10.3390\/jcm13247662.","DOI":"10.3390\/jcm13247662"},{"key":"4750_CR20","unstructured":"R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2024. R Core Team, Vienna, Austria. [Online]. Available: https:\/\/www.R-project.org\/."},{"key":"4750_CR21","doi-asserted-by":"publisher","first-page":"870067","DOI":"10.3389\/fmed.2022.870067","volume":"9","author":"J Gubensek","year":"2022","unstructured":"Gubensek J, et al. Comparable triglyceride reduction with plasma exchange and insulin in acute pancreatitis - a randomized trial. Front Med (Lausanne). 2022;9:870067. https:\/\/doi.org\/10.3389\/fmed.2022.870067.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"4750_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/1744-9987.12428","volume":"20","author":"A Kandus","year":"2016","unstructured":"Kandus A, Buturovi\u0107 Ponikvar J, Mlin\u0161ek G, Oblak M, Arnol M. Kidney transplantation in Slovenia from 1970 to 2015. Therapeutic Apheresis Dialysis. 2016;20(3):229\u201333. https:\/\/doi.org\/10.1111\/1744-9987.12428.","journal-title":"Therapeutic Apheresis Dialysis"},{"key":"4750_CR23","doi-asserted-by":"publisher","unstructured":"M\u00f6rtzell M, Henriksson, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016 Feb;54(1):2\u201315. https:\/\/doi.org\/10.1016\/j.transci.2016.01.003.","DOI":"10.1016\/j.transci.2016.01.003"},{"key":"4750_CR24","doi-asserted-by":"publisher","unstructured":"Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Therapher Dial. 2005 Oct;9(5):391\u201395. https:\/\/doi.org\/10.1111\/j.1744-9987.2005.00319.x.","DOI":"10.1111\/j.1744-9987.2005.00319.x"},{"key":"4750_CR25","doi-asserted-by":"publisher","unstructured":"Brunetta Gavrani\u0107 B, Ba\u0161i\u0107-Juki\u0107 N, Kes P. Changes in indications for therapeutic plasma exchange over the last 27 years in croatia: therapeutic plasma exchange in Croatia. Therapeutic Apheresis Dialysis. 2011 Dec;15(6):587\u201392. https:\/\/doi.org\/10.1111\/j.1744-9987.2011.00986.x.","DOI":"10.1111\/j.1744-9987.2011.00986.x"},{"key":"4750_CR26","doi-asserted-by":"publisher","unstructured":"Doberer K, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation. 2021 Feb;105(2):451\u201357. https:\/\/doi.org\/10.1097\/TP.0000000000003247.","DOI":"10.1097\/TP.0000000000003247"},{"key":"4750_CR27","doi-asserted-by":"publisher","unstructured":"Gubensek J, et al. Treatment of hyperlipidemic acute pancreatitis with plasma exchange: a single-center experience. Ther Apher Dial. 2009 Aug;13(4):314\u20137. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00731.x.","DOI":"10.1111\/j.1744-9987.2009.00731.x"},{"key":"4750_CR28","doi-asserted-by":"publisher","unstructured":"Martin IW, Katus MC, Martin C-LB, Szczepiorkowski ZM, Gorham JD, Dunbar NM. Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia. J Clin Apher. 2016 Oct;31(5):419\u201322. https:\/\/doi.org\/10.1002\/jca.21419.","DOI":"10.1002\/jca.21419"},{"key":"4750_CR29","doi-asserted-by":"publisher","unstructured":"Heigl F, et al. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? Atheroscler Suppl. 2019 Dec;40:23\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.038.","DOI":"10.1016\/j.atherosclerosissup.2019.08.038"},{"key":"4750_CR30","doi-asserted-by":"publisher","unstructured":"Heigl F, et al. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany\u2019s largest apheresis center). Atheroscler Suppl. 2009 Dec;10(5):137\u201341. https:\/\/doi.org\/10.1016\/S1567-5688(09)71829-X.","DOI":"10.1016\/S1567-5688(09)71829-X"},{"key":"4750_CR31","doi-asserted-by":"publisher","unstructured":"Sutton D, Nair R, Rock G. Complications of plasma exchange. Transfusion. 1989 Feb;29(2):124\u20137. https:\/\/doi.org\/10.1046\/j.1537-2995.1989.29289146829.x.","DOI":"10.1046\/j.1537-2995.1989.29289146829.x"},{"key":"4750_CR32","doi-asserted-by":"publisher","unstructured":"Codron P, et al. Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies: a 10-year retrospective study. J Clin Apher. 2017 Dec;32(6):413\u201322. https:\/\/doi.org\/10.1002\/jca.21530","DOI":"10.1002\/jca.21530"},{"key":"4750_CR33","doi-asserted-by":"publisher","unstructured":"Cid J, et al. The Barcelona hospital Cl\u00ednic therapeutic apheresis database. J Clin Apher. 2018 June;33(3):259\u201364. https:\/\/doi.org\/10.1002\/jca.21587.","DOI":"10.1002\/jca.21587"},{"issue":"1","key":"4750_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jca.2920090102","volume":"9","author":"D Couriel","year":"1994","unstructured":"Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis. 1994;9(1):1\u20135. https:\/\/doi.org\/10.1002\/jca.2920090102.","journal-title":"J Clin Apheresis"},{"issue":"4","key":"4750_CR35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/1744-9987.13799","volume":"26","author":"M Golsorkhi","year":"2022","unstructured":"Golsorkhi M, Azarfar A, Abdipour A. Vascular access in therapeutic apheresis: one size does not fit all. Therapeutic Apheresis Dialysis. 2022;26(4):694\u201316. https:\/\/doi.org\/10.1111\/1744-9987.13799.","journal-title":"Therapeutic Apheresis Dialysis"},{"issue":"3","key":"4750_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/jca.21778","volume":"35","author":"D Barth","year":"2020","unstructured":"Barth D, et al. Peripheral vascular access for therapeutic plasma exchange: A practical approach to increased utilization and selecting the most appropriate vascular access. J Clin Apheresis. 2020;35(3):178\u201387. https:\/\/doi.org\/10.1002\/jca.21778.","journal-title":"J Clin Apheresis"},{"key":"4750_CR37","doi-asserted-by":"publisher","unstructured":"Doherty DJ, Pottle A, Malietzis G, Hakim N, Barbir M, Crane JS. Vascular access in lipoprotein apheresis: a retrospective analysis from the uk\u2019s largest lipoprotein apheresis centre. J Vasc Access. 2018 Jan;19(1):52\u20137. https:\/\/doi.org\/10.5301\/jva.5000755.","DOI":"10.5301\/jva.5000755"},{"key":"4750_CR38","doi-asserted-by":"publisher","unstructured":"Vajdi\u010d Trampu\u017e B, Arnol M, Guben\u0161ek J, Ponikvar R, Buturovi\u0107 J, Ponikvar. A national cohort study on Hemodialysis arteriovenous fistulas after kidney transplantation - long-term patency, use and complications. BMC Nephrol. 2021 Oct;22(1):344. https:\/\/doi.org\/10.1186\/s12882-021-02550-4.","DOI":"10.1186\/s12882-021-02550-4"},{"key":"4750_CR39","doi-asserted-by":"publisher","unstructured":"Kundrapu S, Datla S, Griffin V, Maitta RW. Adverse events during apheresis: a 10-year experience at a tertiary academic medical center. J Clin Apher. 2019 Oct;34(5):528\u201336. https:\/\/doi.org\/10.1002\/jca.21706.","DOI":"10.1002\/jca.21706"},{"key":"4750_CR40","doi-asserted-by":"publisher","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994 June;23(6):817\u201327. https:\/\/doi.org\/10.1016\/s0272-6386(12)80135-1.","DOI":"10.1016\/s0272-6386(12)80135-1"},{"key":"4750_CR41","doi-asserted-by":"publisher","unstructured":"Mickiewicz A et al. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: three year experience at a lipoprotein apheresis center. Cardiol J. 2020 Jan;26(6):669\u201379. https:\/\/doi.org\/10.5603\/CJ.a2018.0100.","DOI":"10.5603\/CJ.a2018.0100"},{"key":"4750_CR42","doi-asserted-by":"publisher","unstructured":"Krieter DH, et al. Contact activation in low-density lipoprotein apheresis systems. Artif Organs. 2005 Jan;29(1):47\u201352. https:\/\/doi.org\/10.1111\/j.1525-1594.2004.29007.x.","DOI":"10.1111\/j.1525-1594.2004.29007.x"},{"key":"4750_CR43","doi-asserted-by":"publisher","unstructured":"Antonic M, Gubensek J, Buturovic-Ponikvar J, Ponikvar R. Treatment efficacy and safety during plasma exchange with citrate anticoagulation: a randomized study of 4 versus 15% citrate. Artif Organs. 2016 Apr;40(4):368\u201375. https:\/\/doi.org\/10.1111\/aor.12559.","DOI":"10.1111\/aor.12559"},{"key":"4750_CR44","doi-asserted-by":"publisher","unstructured":"Sirignano RM, Paden ML, Fasano R, Meyer EK. Epidemiology of therapeutic apheresis with a multidisciplinary approach at a high volume pediatric center. J Clin Apher. 2018 June;33(3):297\u2013302. https:\/\/doi.org\/10.1002\/jca.21604.","DOI":"10.1002\/jca.21604"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04750-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04750-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04750-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:06:01Z","timestamp":1770645961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04750-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4750"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04750-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study conforms to the provisions of the Declaration of Helsinki and was approved by the National Medical Ethics Committee (Ref. No. 0120\u2013441\/2022\/3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All personal data were anonymized before the publication. The need for informed consent was waived by the National Medical Ethics Committee (Ref. No. 0120\u2013441\/2022\/3).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}